Schouten H C, Bierman P J, Vaughan W P, Kessinger A, Vose J M, Weisenburger D D, Armitage J O
Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68105-1065.
Blood. 1989 Nov 15;74(7):2579-84.
Patients with disseminated follicular non-Hodgkin's lymphoma (NHL) are only occasionally cured with standard chemotherapy regimens. Although most of these tumors are initially responsive to chemotherapy, in 40% to 70% of patients the lymphoma will eventually transform to an NHL of higher grade malignancy and a poorer prognosis. We treated 18 patients having an original diagnosis of follicular NHL with high-dose therapy and autologous bone marrow transplantation. The lymphomas of 10 of the patients had already undergone histologic transformation and eight still had a follicular histologic pattern. The former group had been followed for a longer time from the diagnosis of NHL and had been more extensively treated with conventional chemotherapy regimens. All eight patients with follicular NHL at the time of transplantation are alive for 246+ to 1,804+ days and seven of the patients are in complete remission. In contrast, of the 10 patients in histologic transformation only 1 is alive and in CR. This reflects the inability of these patients to tolerate the high-dose chemotherapy and myelosuppression as well as resistance of their lymphoma to this therapy. This difference in survival between the two groups was highly significant (P = .002). We conclude that the outcome of patients with follicular NHL transplanted early before histologic transformation is better than for those who are transplanted later in the course of their illness. Because of the relapsing behavior of follicular NHL, a longer follow-up is necessary to prove any impact on the natural history of the disease.
播散性滤泡性非霍奇金淋巴瘤(NHL)患者仅偶尔能通过标准化疗方案治愈。尽管这些肿瘤大多数最初对化疗有反应,但40%至70%的患者淋巴瘤最终会转变为更高恶性程度、预后更差的NHL。我们对18例最初诊断为滤泡性NHL的患者进行了大剂量治疗和自体骨髓移植。其中10例患者的淋巴瘤已发生组织学转化,8例仍具有滤泡性组织学模式。前一组自NHL诊断后随访时间更长,接受传统化疗方案的治疗也更广泛。移植时仍为滤泡性NHL的8例患者均存活246天以上至1804天以上,7例患者完全缓解。相比之下,10例组织学转化患者中仅1例存活且处于完全缓解状态。这反映出这些患者无法耐受大剂量化疗和骨髓抑制,以及他们的淋巴瘤对这种治疗具有抗性。两组患者的生存差异具有高度显著性(P = .002)。我们得出结论,在组织学转化前早期进行移植的滤泡性NHL患者的预后优于病程后期进行移植的患者。由于滤泡性NHL具有复发特性,需要更长时间的随访来证明对疾病自然史的任何影响。